Navigation Links
Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
Date:1/11/2011

WALTHAM, Mass., Jan. 11, 2011 /PRNewswire/ -- Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC).  The data is being published in the January 15, 2011 issue of Cancer Research.

"These findings demonstrate the promise for epigenetic therapy in cancer management and provide us with important new insights to guide further development of human treatments for lung cancer," said Steven Belinsky, Ph.D., vice president for academic research, director, lung cancer program, Lovelace Respiratory Research Institute.  "Epigenetic therapy may circumvent the problem of tumor heterogeneity by inducing the re-expression of multiple tumor suppressor genes essential for abrogating cancer cell survival and proliferation."

The purpose of the study was to determine the efficacy of a demethylating agent, Vidaza, alone or in combination with a histone deacetylase inhibitor (HDACi), entinostat, on the growth of tumors engrafted in the lungs of the nude rat and on reprogramming of the epigenome.  Researchers developed an orthotopic lung cancer model in which xenografts of human lung cancer-derived cell lines are efficiently engrafted throughout the lungs of the nude rat.  The study showed that combining the HDACi entinostat with the demethylating agent Vidaza profoundly affected growth of K-ras/p53 mutant lung adenocarcinomas engrafted orthotopically in immunocompromised nude rats by targeting and ablating pleomorphic cells that occupied up to 75% of the tumor masses.

"These exciting findings of entinostat combined with Vidaza in a validated animal model of lung cancer support ongoing clinical efforts with epigenetic therapy in solid tumors and provide a foundation for identification and  development of patient  selection tools for this novel therapeutic approach," said Joanna Horobin, M.D., president and chief executive officer of Syndax.  "These results have been confirmed in a phase 2 clinical trial of entinostat and Vidaza in patients with advanced NSCLC who had progressed after a median of three prior therapies giving us hope that this combination could become a much needed treatment option in the future for this patient population."

Similar results to the response seen in this orthotopic model were seen in a phase 2 trial of Vidaza and entinostat in heavily pretreated patients with relapsed advanced  NSCLC. Progressive disease was controlled in 10 of 28 evaluable patients, including one complete response, one partial response and eight patients with disease stabilization of at least four months. These results were presented by Dr. Rosalyn Juergens from Johns Hopkins University School of Medicine at the 13th  World Conference on Lung Cancer in 2009.

About Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer, a disease in which malignant cells form in the tissues of the lungs, is the most common type of lung cancer.  The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Each year there are more than 200,000 cases of newly diagnosed advanced NSCLC.  About 60% of patients present with advanced NSCLC, meaning it has spread beyond the lung, when they are seen by a doctor.  The five-year survival rate is less than 10 percent for patients with advanced NSCLC.

About Entinostat

Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat has shown promise in phase two randomized clinical trials and is being studied in numerous phase 2 clinical trials including a trial in advanced breast cancer patients in combination with aromatase inhibitors and in a Hodgkin's lymphoma trial as a single agent. Under a Cooperative Research and Development Agreement (CRADA) with the NCI, entinostat also is being studied in multiple types of solid tumors and hematologic cancers.

Research has shown that HDACs are involved in the expression of various genes that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.  Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.

Contact Information

E. Blair Schoeb

Syndax Pharmaceuticals, Inc Tel: 908-277-0386 bschoeb@syndax.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
2. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
3. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
6. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
7. Amarin Announces Successful Completion of Offering of American Depositary Shares
8. Celleration, Inc. Announces Close of $8 Million Series E Financing
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
11. Dehaier Medical Announces Participation in Arab Health 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):